Beijing Zhipeptide Biopharmaceutical Technology

Beijing Zhipeptide Biopharmaceutical Technology is a clinical-stage biotechnology company focused on the discovery and development of innovative peptide therapeutics for metabolic diseases. The company utilizes an advanced AI-driven design platform to engineer long-acting peptides with improved efficacy and safety profiles. Its lead programs include ZP-001, a long-acting GLP-1 receptor agonist, and ZP-002, a dual GLP-1/GIP receptor agonist, targeting obesity and type 2 diabetes. Zhipeptide is backed by prominent venture capital firms and aims to become a leader in the global peptide drug market through its proprietary engineering technologies.